急性呼吸窘迫综合征延长静脉-静脉体外膜氧合支持的患病率与生存分析:体外生命支持组织登记研究
该回顾性观察队列研究基于体外生命支持组织登记库,纳入2012年1月至2022年12月因ARDS接受VV ECMO支持的13,681例成人患者。4,040例(29.5%)支持≥21天,975例(7.1%)支持≥50天。延长支持组出院存活率低于短时支持组(46.5% vs. 59.7%;p<0.001)。但在支持≥21天的患者中,ECMO时长与死亡率无显著相关(未校正OR 0.99;95%CI 0.98-1.01;p=0.87;校正OR 0.99;95%CI 0.97-1.02;p=0.48),支持≥120天的113例中52例(46.0%)最终出院存活。提示对已存活≥21天的患者,不应仅因支持时间长而放弃。
要点
- 在ARDS接受VV ECMO支持存活≥21天的患者中,ECMO持续时间与住院死亡率无显著相关(校正OR 0.99;95%CI 0.97-1.02;p=0.48)。
- 支持≥120天的113例患者中,52例(46.0%)最终出院存活,提示临床恢复可在极长程VV ECMO支持后发生。
- 延长VV ECMO支持(≥21天)占29.5%(4,040/13,681),≥50天占7.1%(975/13,681),比例可观且在增加。
- 延长支持组出院存活率低于短时支持组(46.5% vs. 59.7%;p<0.001),但该比较未校正混杂因素。
适用人群与场景
- 体外生命支持组织登记库中2012年1月至2022年12月因ARDS接受VV ECMO支持的成人患者,共13,681例。
研究设计与关键结果
- 研究类型:回顾性观察队列研究,基于体外生命支持组织登记库,纳入13,681例因ARDS接受VV ECMO支持的成人患者。
- 延长支持比例:4,040例(29.5%)接受VV ECMO支持≥21天,975例(7.1%)支持≥50天。
- 出院存活:延长支持组46.5% vs. 短时支持组59.7%(p<0.001)。
- 在支持≥21天的患者中,ECMO持续时间与死亡率无显著相关:未校正OR 0.99(95%CI 0.98-1.01;p=0.87),校正OR 0.99(95%CI 0.97-1.02;p=0.48)。
- 支持≥120天的患者(n=113)中,52例(46.0%)最终出院存活。
证据类型、等级与局限
- 证据类型:回顾性观察队列研究(基于登记库)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在VV ECMO支持≥21天仍存活的患者中,支持时长不能预测出院存活,即使极长程支持后仍可能临床恢复。
- 对已接受VV ECMO支持≥21天的ARDS患者,不应仅因支持时间延长而判定无恢复可能(作者结论)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: To examine trends in utilization and outcomes among patients with the acute respiratory distress syndrome (ARDS) requiring prolonged venovenous extracorporeal membrane oxygenation (VV ECMO) support.
DESIGN: Retrospective observational cohort study.
SETTING: Adult patients in the Extracorporeal Life Support Organization registry.
PATIENTS: Thirteen thousand six hundred eighty-one patients that required ECMO for the support of ARDS between January 2012 and December 2022.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: Mortality while supported with VV ECMO and survival to hospital discharge based on ECMO duration were examined utilizing multivariable logistic regression. Among the 13,681 patients supported with VV ECMO, 4,040 (29.5%) were supported for greater than or equal to 21 days and 975 (7.1%) for greater than or equal to 50 days. Patients supported with prolonged VV ECMO were less likely to be discharged alive from the hospital compared with those with short duration of support (46.5% vs. 59.7%; p < 0.001). However, among patients supported with VV ECMO greater than or equal to 21 days, duration of extracorporeal life support was not significantly associated with mortality (odds ratio [OR], 0.99; 95% CI, 0.98-1.01; p = 0.87 and adjusted OR, 0.99; 95% CI, 0.97-1.02; p = 0.48). Even in those supported with VV ECMO for at least 120 days (n = 113), 52 (46.0%) of these patients were ultimately discharged alive from the hospital.
CONCLUSIONS: Prolonged VV ECMO support of ARDS has increased and accounts for a substantial portion of cases. Among patients that survive for greater than or equal to 21 days while receiving VV ECMO support, duration is not predictive of survival to hospital discharge and clinical recovery may occur even after very prolonged VV ECMO support.
参考来源
- Chandel A, Fabyan KD, Mendelsohn S, et al. Prevalence and Survival of Prolonged Venovenous Extracorporeal Membrane Oxygenation for Acute Respiratory Distress Syndrome: An Analysis of the Extracorporeal Life Support Organization Registry. Crit Care Med. 2024. PMID: 38752812. doi:10.1097/CCM.0000000000006200
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。